FIELD: medicine.
SUBSTANCE: invention relates to ionizable lipids of formula I or their forms in the form of pharmaceutically acceptable salts, which can be useful for enhancing the delivery of therapeutic agents to patients. In formula I, n and m are independently 1, 2, 3, or 4; R1 and R2 are independently C10-18alkyl or C12-18alkenyl; when X is S, L is C1-4alkylene, -S-C1-4alkylene, -O-C1-4alkylene, -O-C(O)-C1-4alkylene, -S(O)2-C1-4alkylene or or when X is -CH2-, O or absent, L is -S-C1-4alkylene, -O-C(O)-C1-4alkylene, -S(O)2-C1-4alkylene or
.
.
EFFECT: invention also relates to a pharmaceutical composition for enhancing the delivery of therapeutic agents comprising lipid compounds of formula I, a drug carrier comprising the composition, a pharmaceutical composition based on the drug carrier, and a method for delivering the drug.
45 cl, 4 dwg, 1 tbl, 24 ex
алкилен - alkylene
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS FOR TARGETED DELIVERY OF MEDICINE AND ENHANCED SIPHK ACTIVITY | 2012 |
|
RU2632888C2 |
COMPOUNDS FOR TARGETED DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | 2012 |
|
RU2769872C2 |
COMPOUNDS SUITABLE FOR THERAPY AGAINST HIV | 2019 |
|
RU2806030C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
DISPOSABLE SYSTEM FOR STERILE OBTAINING OF LIPIDS AND NUCLEIC ACIDS PARTICLES | 2012 |
|
RU2642640C2 |
COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL DISEASES | 2013 |
|
RU2684097C2 |
ANTIVIRAL COMPOUNDS | 2010 |
|
RU2541571C2 |
METHOD FOR PRODUCTION OF JAK INHIBITORS AND THEIR INTERMEDIATE COMPOUNDS | 2019 |
|
RU2786361C2 |
BIFUNCTIONAL CYTOTOXIC AGENTS | 2015 |
|
RU2669807C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
Authors
Dates
2018-06-19—Published
2013-06-07—Filed